Liproxstatin-1: Potent Ferroptosis Inhibitor with IC50 22 nM

Executive Summary: Liproxstatin-1 is a highly potent and selective inhibitor of ferroptosis, with an IC50 of approximately 22 nM under standardized cell-based assay conditions [APExBIO]. It protects against lipid peroxidation in GPX4-deficient cell models and in animal models of organ injury [Yu et al., 2026]. Liproxstatin-1 is insoluble in water but dissolves efficiently in DMSO and ethanol with gentle warming and sonication, making it compatible with most cell-based protocols. Its mechanism centers on direct inhibition of lipid peroxide accumulation, the hallmark of ferroptosis. The compound is supplied by APExBIO (SKU B4987) as a research tool in the study of iron-dependent cell death pathways and pathological lipid peroxidation.

Biological Rationale

Ferroptosis is a regulated cell death process distinct from apoptosis, necrosis, and cuproptosis. It is defined by iron-dependent lipid peroxidation and loss of plasma membrane integrity [Yu et al., 2026]. Ferroptosis is implicated in acute organ injuries, neurodegeneration, and cancer therapy resistance. GPX4 (glutathione peroxidase 4) is a key cellular enzyme that prevents ferroptosis by reducing lipid hydroperoxides. Inhibition or genetic deletion of GPX4 triggers ferroptosis, making GPX4-deficient models essential for mechanistic studies. Liproxstatin-1 enables the precise dissection of this pathway by selectively blocking lipid peroxidation, providing a benchmark tool for ferroptosis research.

Mechanism of Action of Liproxstatin-1

Liproxstatin-1 acts by scavenging lipid peroxyl radicals, thereby preventing the accumulation of cytotoxic lipid peroxides. The compound demonstrates nanomolar potency (IC50 ≈ 22 nM) in cell-based ferroptosis assays [reference]. It is especially effective in GPX4-deficient cells, which are otherwise hypersensitive to ferroptosis inducers such as RSL3. Liproxstatin-1 does not inhibit other regulated cell death pathways (e.g., apoptosis, necroptosis, cuproptosis) at effective concentrations, confirming its selectivity [Yu et al., 2026]. Mechanistically, it halts the lipid peroxidation chain reaction at the propagation phase, thereby maintaining membrane integrity and cell viability.

Evidence & Benchmarks

• Liproxstatin-1 inhibits ferroptosis with an IC50 of ~22 nM in GPX4-deficient cell models under serum-supplemented, 37°C, 5% CO₂ culture conditions (APExBIO).
• It prevents lipid peroxidation induced by agents like RSL3 and erastin in standardized in vitro assays (baxinhibitor.com).
• Liproxstatin-1 prolongs survival in mice with conditional kidney-specific Gpx4 deletion, demonstrating in vivo efficacy (Yu et al., 2026).
• It significantly reduces tissue damage in models of hepatic ischemia/reperfusion injury (tb-dry.com).
• The compound is insoluble in water but soluble at ≥10.5 mg/mL in DMSO and ≥2.39 mg/mL in ethanol with ultrasonic treatment (APExBIO).

For a comparison of Liproxstatin-1's mechanism with other ferroptosis inhibitors and insights into iron-dependent cell death, see this article, which provides a molecular perspective on lipid peroxidation pathways. This article extends these findings by offering structured benchmarks and workflow guidance.

Applications, Limits & Misconceptions

Liproxstatin-1 is widely used in the following research contexts:

• Dissecting the ferroptosis pathway in cell lines and primary cells.
• Protecting against ferroptosis-induced organ injury (renal, hepatic) in animal models.
• Validating the role of GPX4 and lipid peroxidation in disease models.
• Screening for synthetic lethality or drug synergy in iron-dependent cell death contexts.

For advanced applications and the mechanistic landscape, see this article, which Liproxstatin-1's role in oxidative stress-related pathologies is contrasted with its benchmarked application data here.

Common Pitfalls or Misconceptions

• Liproxstatin-1 is not active against apoptosis, necroptosis, or cuproptosis at concentrations effective for ferroptosis inhibition.
• It does not reverse established organ injury; efficacy is limited to prevention or acute intervention phases.
• Its poor water solubility requires careful solvent preparation (DMSO or ethanol) for in vitro and in vivo use.
• Stability of stock solutions is limited; solutions should be prepared fresh or stored short-term at -20°C.
• Effects in human clinical settings remain unproven; all applications are for research use only.

For a guide to protocol pitfalls and compatibility with various assays, see this article, which this dossier updates by providing direct quantitative benchmarks and solubility parameters.

Workflow Integration & Parameters

• Solubility: Liproxstatin-1 is insoluble in water. For cell-based assays, dissolve in DMSO (≥10.5 mg/mL) or ethanol (≥2.39 mg/mL) with gentle warming and sonication (APExBIO).
• Storage: Store powder at -20°C, desiccated. Prepared solutions should be used promptly or stored no longer than a few days at -20°C.
• Working Concentration: Typical in vitro studies use 10–100 nM; titrate as needed for specific cell lines or primary cells.
• Controls: Include vehicle-only and positive ferroptosis inducers (e.g., RSL3, erastin) for benchmarking.
• Readouts: Measure lipid peroxidation (e.g., BODIPY 581/591 C11 dye) and cell viability (e.g., MTT, CellTiter-Glo) to confirm ferroptosis inhibition.

For extended workflow guides and scenario-driven Q&A, refer to this protocol article.

Conclusion & Outlook

Liproxstatin-1 (SKU B4987, APExBIO) is a potent, selective ferroptosis inhibitor that is now a gold-standard tool for dissecting iron-dependent cell death mechanisms. Its nanomolar potency, clear solubility guidelines, and validated efficacy in preclinical models make it indispensable for ferroptosis research. Future studies may clarify its therapeutic potential and expand its use in combination with emerging cell death modulators. For ordering or product details, refer to the official Liproxstatin-1 page.